Bruker Corporation $BRKR Shares Bought by Old West Investment Management LLC

Old West Investment Management LLC grew its stake in Bruker Corporation (NASDAQ:BRKR) by 740.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 234,844 shares of the medical research company’s stock after buying an additional 206,899 shares during the quarter. Bruker accounts for about 3.2% of Old West Investment Management LLC’s portfolio, making the stock its 12th largest holding. Old West Investment Management LLC’s holdings in Bruker were worth $9,676,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of BRKR. Nisa Investment Advisors LLC raised its position in Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares in the last quarter. Huntington National Bank boosted its position in Bruker by 750.0% in the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after purchasing an additional 645 shares in the last quarter. Allworth Financial LP grew its stake in shares of Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after purchasing an additional 364 shares during the period. Spire Wealth Management purchased a new position in shares of Bruker during the 2nd quarter valued at approximately $32,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 745 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 1.6%

Shares of Bruker stock opened at $41.79 on Friday. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $64.64. The firm has a market capitalization of $6.35 billion, a PE ratio of 80.37, a P/E/G ratio of 5.31 and a beta of 1.26. The firm’s 50-day moving average price is $35.83 and its 200 day moving average price is $37.18.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.33 by $0.12. The company had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.Bruker’s quarterly revenue was down .5% on a year-over-year basis. During the same period in the previous year, the business earned $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, sell-side analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be issued a $0.05 dividend. The ex-dividend date is Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s dividend payout ratio is presently -125.00%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Barclays raised their price target on shares of Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. UBS Group raised their target price on Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a report on Wednesday, October 8th. Jefferies Financial Group set a $60.00 price objective on Bruker and gave the company a “buy” rating in a report on Monday, August 4th. Finally, TD Cowen upped their target price on Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a research note on Tuesday, November 4th. Five equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $48.30.

Insider Buying and Selling

In related news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director owned 35,212 shares in the company, valued at approximately $1,373,268. This represents a 15.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 27.30% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.